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Background. For many people with HIV (PWH), taking antiretroviral therapy (ARV) every day is difficult.
Methods. Average adherence (Av-Adh) and log-transformed treatment interruption (TI) to ARV were prospectively measured over 
6 months using electronic drug monitoring (EDM) in several cohorts of PWH. Multivariate linear regression models including baseline 
confounders explored the influence of EDM-defined adherence (R2) on 6-month log10 HIV-RNA. Multivariate logistic regression models 
were used to compare the risk of HIV-RNA detection (VR) within subgroups stratified by lower (≤95%) and higher (>95%) Av-Adh.
Results. Three hundred ninety-nine PWH were analyzed with different ARVs: dolutegravir (n = 102), raltegravir (n = 90), boosted PI 
(bPI; n = 107), and NNRTI (n = 100). In the dolutegravir group, the influence of adherence pattern measures on R2 for HIV-RNA levels was 
marginal (+2%). Av-Adh, TI, and Av-Adh × TI increased the R2 for HIV-RNA levels by 54% and 40% in the raltegravir and bPI treatment 
groups, respectively. TI increased the R2 for HIV-RNA levels by 36% in the NNRTI treatment group. Compared with the dolutegravir-
based regimen, the risk of VR was significantly increased for raltegravir (adjusted odds ratio [aOR], 45.6; 95% CI, 4.5–462.1; P = .001), 
NNRTIs (aOR, 24.8; 95% CI, 2.7–228.4; P = .005), and bPIs (aOR, 28.3; 95% CI, 3.4–239.4; P = .002) in PWH with Av-Adh ≤95%. Among 
PWH with >95% Av-Adh, there were no significant differences in the risk of VR among the different ARVs.
Conclusions. These findings support the concept that dolutegravir in combination with 2 other active ARVs achieves greater 
virological suppression than older ARVs, including raltegravir, NNRTI, and bPI, among PWH with lower adherence.
Keywords.  adherence; dolutegravir; PWH; missed doses.
Suboptimal adherence to antiretroviral therapy can result in 
insufficient viral suppression [1,2] and promotes the emer-
gence of drug-resistant viral strains [3]. A landmark study with 
unboosted protease inhibitor antiretrovirals (ARVs) proposed 
that >95% adherence was required to achieve and maintain vi-
rological suppression, which led to the concept that an unde-
tectable HIV viral load (VL) was equivalent to full adherence 
[1]. Modern antiretroviral therapies with once-daily dosing and 
low pill burden improved the level of adherence compared with 
more complex regimens [4,5]. Simpler regimens have improved 
adherence [4,6], and potent regimens with more favorable phar-
macokinetic profiles have allowed more forgiveness with regard 
to missed doses. Studies investigating non-nucleoside reverse 
transcriptase inhibitors (NNRTI), boosted protease inhibitors 
(bPIs), and integrase strand-transfer inhibitors (INSTI) as a part 
of ARV drug combinations demonstrated that the lowest level 
of ARV adherence required to sustain virological suppression 
may be ~80% [7,8]. However, the methods used to measure ad-
herence, such self-report and pharmacy refills, did not capture 
treatment interruptions, another independent driver of viro-
logical failure [9] and resistance [10]. In addition, these studies 
did not specifically investigate second-generation INSTI-based 
ARV combinations, despite their being widely recommended.
Real-world studies of the “forgiveness” to missed doses 
of ARV regimen are important, as they may help to predict 
regimen durability and risk of resistance in a context where 
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suboptimal adherence is probably common [11]. We hypothe-
sized that the pharmacokinetic profile and genetic barrier pro-
vided by second-generation INSTIs, namely dolutegravir-based 
ARV combinations, would allow a high rate of virological sup-
pression at low to moderate adherence levels. Therefore, we 
aimed to investigate the patterns of adherence to dolutegravir 
associated with virological replication in comparison with older 
third agents.
METHODS
Study Design and Participants
We conducted an international multicenter prospective 
cohort study of people with HIV (PWH) treated with a 
dolutegravir-based regimen. The DOLUTECAPS study 
took place in France and Switzerland between May 2015 
and December 2018. The details of the inclusion criteria 
are described in the clinical trial registration: https://
clinicaltrials.gov/ct2/show/NCT02878642. Briefly, adults 
with HIV starting once- or twice-a-day dolutegravir-
based regimens were included at the physician’s discretion. 
Because we were interested in covering a large range of dif-
ferent pill-taking behaviors, the participation of PWH per-
ceived by their treating physician to be at risk of suboptimal 
adherence was encouraged. Subjects had a genotypic sen-
sitivity score of ≥3, including dolutegravir. The genotypic 
sensitivity score represents the total number of ARV drugs 
in the regimen to which a patient’s HIV is susceptible (score 
1), possibly susceptible (score 0.5), or resistant (score 0), ac-
cording to version 30 of the ANRS AC-43 resistance group 
algorithm (http://www.hivfrenchresistance.org/2019/tab6.
html). We did not include people using pillbox organizers 
and those who were not responsible for taking their anti-
retroviral pills. Three groups of participants were defined: 
antiretroviral-naïve individuals who initiated dolutegravir 
(STARTING group), antiretroviral-experienced individ-
uals who switched to dolutegravir for virological failure 
(FAILING group), and antiretroviral-experienced indi-
viduals who switched to dolutegravir while HIV-RNA was 
supressed (SWITCHING group). Dolutegravir combined 
with abacavir/lamivudine as a single-tablet regimen and 
multitablet regimens containing dolutegravir plus at least 2 
other active ARVs were allowed.
Several centers from our group have incorporated the use 
of EDM devices in routine practice. In addition, we previ-
ously investigated adherence–virological outcome relation-
ships for older ARVs such as NNRTIs [12], bPIs [13,14], and 
raltegravir [15]. We contrasted the DOLUTECAPS cohort find-
ings with other antiretroviral therapies from our EDM database 
(Supplementary Figure 1). All participants were followed pro-
spectively with electronic adherence monitoring and an HIV-
RNA determination at 6 months as the primary outcome.
Data Collection and Adherence Pattern Measures
Baseline characteristics including sociodemographic factors 
and clinical characteristics were collected at baseline for the 4 
groups: dolutegravir, raltegravir, bPIs, and NNRTIs. Patients 
were asked to use electronic drug monitoring (EDM; Aardex, 
Switzerland) devices to prospectively characterize their pat-
tern of adherence to the third agent for 6  months. The same 
monitoring strategy and devices were used for the 4 groups. 
Other ARV pills (eg, backbone nucleos/tide reverse transcrip-
tase inhibitors), if any, were not monitored. Two measures were 
extracted from electronic dosing history for each participant: 
(1) the average percent dose adherence corresponding to the 
number of observed electronic pill cap opening events divided 
by the expected events; (2) the log10-transformed duration of 
the longest treatment interruption (in hours). EDM records 
were read and reviewed at all study visits and allowed partici-
pants to add any doses taken when they knew they did not use 
the device. Seventeen participants with no EDM events during 
the 2 weeks prior to month 6 were excluded. This is because 
nonpersistence to any short-acting antiretroviral drug is known 
to be associated with virological replication in most situations.
Patient Consent Statement
The Institutional Review Board of the University of Caen, France 
(which covers all French sites), and the Committee on Human 
Subjects Research of the University of Lausanne, Switzerland, 
approved all study procedures, and the participants provided 
written informed consent.
Outcomes
The primary outcome was HIV-1 RNA in plasma, measured 
using the test available in each center with a limit of detection 
≤50 HIV-1 RNA copies/mL. We defined virological replication 
as failure to suppress or sustain HIV-RNA to <50 copies/mL 
at 6 months. A value of ≤50 was imputed to PWH who had a 
lower limit of detection >50 copies/mL for 34 participants in the 
NNRTI group and 56 participants in the bPI treatment group. 
Emergence of resistance to dolutegravir and to raltegravir was 
investigated by genotyping the integrase coding sequence of the 
virus after the development of virological replication.
Statistical Analysis
Continuous variables were summarized as mean values, me-
dian values, SDs, and interquartile ranges (IQRs), depending 
on their distributions. Dichotomous data were summarized 
as numbers and proportions. Regarding baseline and fol-
low-up characteristics, quantitative variables were compared 
between ARV classes using an analysis of variance or Kruskal-
Wallis test, as appropriate, and qualitative variables were 
compared using the Fisher exact test. In order to characterize 
the adherence pattern associated with HIV-RNA replication, 
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of log HIV-RNA (vertical z-axis) according to the average 
adherence (horizontal x-axis) and log longest treatment in-
terruption (horizontal y-axis). Because the original data did 
not contain enough combinations of x, y, and z values to gen-
erate an empirically derived surface plot with <64% average 
adherence, we censored these observations for data visual-
ization. In addition, we used a smoothing spline interpola-
tion method with λ  =  0.1 as a trade-off between closeness 
to the original data and smoothness. For each antiretroviral 
group, we computed 3 different linear regression models—(i) 
with average adherence (Model 1); (ii) with treatment inter-
ruption (Model 2); (iii) with average adherence, treatment 
interruption, and the product (interaction) of average adher-
ence × treatment interruption (Model 3)—as independent 
covariables with the log HIV-RNA at 6  months as the de-
pendent variable. These models were also adjusted for poten-
tial confounders (age, sex, baseline treatment scenarios [ie, 
naïve, switch, or treatment failure], baseline HIV-RNA, and 
CD4 cell count). The influence of the EDM-defined adher-
ence pattern on 6-month HIV-RNA was assessed in 2 ways: 
(i) by testing the slope of each adherence pattern parameter 
coefficient to 0; (ii) by assessing the incremental R2 value (or 
variance explained) for each model, compared with a model 
without EDM adherence measurement (ie, including only 
baseline factors).
The effect size of factors associated with the probability of vi-
rological detection (HIV-RNA >50 copies/mL) was estimated 
by calculating odds ratios (ORs) and adjusted ORs using uni-
variate and multivariate logistic regression models, respectively. 
This analysis was performed in the overall cohort and in sub-
groups with higher (>95%) and lower (≤95%) average adher-
ence [1]. Analyses were performed using PowerView, version 
2.3.3 (Aardex Group, Sion, Switzerland), and SAS, version 
9.4 (SAS Institute, Cary, NC, USA). All reported P values are 
2-sided, with a P value of ≤.05 denoting statistical significance.
RESULTS
Baseline Characteristics
The baseline characteristics of the participants are shown in 
Table 1. Seventy-two percent of the participants treated with 
a dolutegravir-based regimen were men, and the mean age 
was 47.7 years. Approximately one-quarter of the participants 
treated with a dolutegravir-based regimen were treatment-
naïve at baseline. Fourty-seven (46%) PWH had a plasma HIV-
RNA <50 copies/mL at study entry. The median baseline CD4 
cell count (IQR) was 494 (290–705), and the median baseline 
plasma HIV-RNA level (IQR) was 2.1 (1.6–4.1) log10. The base-
line characteristics from PWH treated with other third agents 
are presented in Table 1. In the NNRTI-based group, the third 
agent was nevirapine for 70 PWH, efavirenz for 12 PWH, and 
rilpivirine for 18 PWH. In the boosted PI group, the third agent 
was lopinavir for 54 PWH, atazanavir for 48 PWH, and other 
boosted PI for 3 PWH.
HIV-RNA at Month 6
In the dolutegravir treatment group (Table 2), 8 PWH had 
low levels of HIV-RNA replication: 5/24 (17%) in the failing 
group (median [range] HIV-RNA, 132 [88–168] cp/mL), 2/26 
(8%) in the starting group (HIV-RNA, 80 and 161 cp/mL), 
and 1/46 (2%) in the switching group (HIV-RNA, 73 cp/mL). 
Among these, 3/8 were amplified, and none demonstrated 
a resistance mutation to the INSTI class. In the raltegravir 
treatment group (Table 2), 18 PWH had HIV-RNA replica-
tion (median [range] HIV-RNA, 362 [57–51 300] copies/mL) 
Table 1. Baseline and Follow-up Characteristics by Antiretroviral Class
Variables Dolutegravir-Based (n = 102) Raltegravir-Based (n = 90) NNRTI-Based (n = 100) bPI-Based (n = 107) P Value
Baseline characteristics
Age, mean (SD), y 47.7 (13.2) 46.2 (11.2) 46.8 (10.6) 41.3 (7.6) <.001
Male, sex, No. (%) 73 (72) 65 (72) 86 (86) 88 (82) .028
CD4+ cells, median (IQR) 494 (290–705) 490 (309–709) 510 (383–723) 311 (229–450) <.001
Treatment groups, no. (%)/log HIV-1 RNA, median [IQR]
 Switched treatment 47 (46)/1.7 69 (77)/1.7 100 (100)/1.7 31 (29)/1.7 <.001
 Treatment-naïve 26 (26)/4.6 [4.0–5.0] 10 (11)/5.4 [3.6–5.5] 0 (0)/- 43 (40)/4.4 [3.8–5.1]
 Failed treatment 29 (28)/3.2 [2.6–4.1] 11 (12)/4.6 [4.0–5.0] 0 (0)/- 33 (31)/2.8 [2.3–3.6]
Backbone
 TDF/FTC or TAF/FTC 22 (22) 49 (54) 22 (22) 56 (52) <.001
 ABC/3TC 47 (46) 6 (7) 38 (38) 10 (9)
 Other NRTI combination 8 (8) 12 (13) 40 (40) 13 (12)
 Other class combination 25 (25) 23 (26) 0 (0) 28 (26)
Adherence follow-up
Average adherence, median (IQR) 96.0 (87.0–99.0) 97.0 (91.0–100.0) 96.0 (84.5–99.0) 95.3 (82.0–100.0) .32
Longest TI, median (IQR), d 2.1 (1.3–2.8) 1.5 (1.0–2.7) 1.3 (1.1–1.9) 2.0 (1.0–7.0) <.001
Abbreviations: 3TC, lamivudine; ABC, abacavir; bPI, boosted protease inhibitor; FTC, emtricitabine; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, 
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and 14/18 were subjected to nucleic acid amplification and 
sequencing: 4 samples harbored INSTI conferring resist-
ance to raltegravir (Q148H, N155H, Q148R, and Y143A). In 
the NNRTI treatment group (Table 2), 12 PWH had HIV-
RNA replication (median [range] HIV-RNA, 854 [66-15 000] 
copies/mL). In the bPI group (Table 2), 26 PWH had HIV-
RNA replication (median [range] HIV-RNA, 11 000 [59–
801  400] copies/mL). No data were available for resistance 
testing in the bPI and NNRTI groups.
Adherence Pattern and HIV-RNA Relationships
Figure 1 displays the 6-month log10 HIV-RNA according to 
the EDM-defined adherence pattern by antiretroviral regimen 
among 399 PWH. As shown in Figure 2A, the surface plot for 
dolutegravir-based triple therapy is flat, indicating a low level of 
HIV-RNA replication regardless of the adherence pattern. None 
of the models including adherence pattern parameters was sig-
nificantly associated with 6-month HIV-RNA level (Figure 2A), 
and the incremental HIV-RNA variance explained by the in-
clusion of adherence pattern variables was minimal (2%). In 
contrast, the adherence patterns were significantly associated 
with the level of virological replication above the detection 
threshold for all older ARVs, with an incremental variance ex-
plained (R2) ranging from 14% (Figure 2D, model 2)  to 54% 
(Figure 2B, model 3). Model 3 had the highest HIV-RNA level 
variance explained for the raltegravir group (Figure 2B) and the 
bPI group (Figure 2D), suggesting that the influence of 1 ad-
herence measure depends on the value of the other. Regarding 
the NNRTI group (Figure 2C), the longer treatment interrup-
tion (model 2)  had the highest variance explained to predict 
HIV-RNA level.
Predictors of HIV-RNA >50 Copies/mL
In the overall cohort, factors associated with virological detec-
tion (ie, probability of 6-month HIV-RNA >50 copies/mL) in 
the univariate and multivariate analyses are shown in Table 2.
In the subgroup analyses based on average adherence, the 
risk of virological detection was similar between all ARVs 
among PWH with >95% adherence levels (Table 3) in the mul-
tivariate analysis. Among PWH with ≤95% adherence levels 
(Table 3) and compared with those receiving a dolutegravir-
based regimen, the risk of virological detection was significantly 
and independently increased for the raltegravir-based regimen, 
NNRTIs, and bPIs in the multivariate analysis.
DISCUSSION
In this cohort of PWH followed by EDM, the adherence 
pattern to dolutegravir-based triple therapy was not a pre-
dictor of suppressed HIV-RNA. This picture contrasts with 
the strong association between adherence pattern and HIV-
RNA level found for older regimens, including raltegravir-, 
NNRTI-, and bPI-based ARV therapies. In addition, 
dolutegravir therapy outperformed all other ARV strategies 
in terms of virological suppression below the limit of detec-
tion among PWH in the lower adherence subgroup in the 
Table 2. Factors Associated With Virological Replication (>50 Copies/mL) at Month 6 in the Overall Cohort (n = 399)
Univariate Analysis Multivariate Analysis
Variables No VR (n = 335) VR (n = 64) P Value aOR [95% CI] P Value
Age, mean (SD), y 44.5 (11.8) 41.6 (11.3) .07 0.88 [0.63–1.22] .44
Male 259 (77.3) 53 (82.8) .41 1.36 [0.6–3.2] .48
CD4 cells, mean (SD) 494 (256) 402 (250) .009 0.97 [0.86–1.14] .92
Log HIV-RNA, mean (SD), cp/mL 2.44 (1.23) 2.90 (1.37) .008 1.61 [0.97–2.68] .07
Third antiretroviral agent   .005   
 Dolutegravir-based 94 (28.1) 8 (12.5)  Ref.  
 Raltegravir-based 72 (21.5) 18 (28.1)  7.7 [2.4–25.2] .0007
 bPI-based 81 (24.2) 26 (40.6)  1.9 [0.6–6.0] .29
 NNRTI-based 88 (26.3) 12 (18.8)  3.4 [0.9–12.7] .07
Treatment group   <.0001   
 Switched treatment 221 (66.0) 26 (40.6)  Ref.  
 Treatment-naïve 70 (20.9) 9 (14.1)  0.6 [0.1–4.2] .63
 Failed treatment 44 (13.1) 29 (41.3)  4.4 [1.4–14.0] .012
Adherence class   <.0001   
 >95% 211 (63.0) 20 (31.2)  Ref.  
 90%–95% 39 (11.6) 3 (4.7)  0.5 [0.1–2.1] .35
 80%–90% 47 (14.0) 5 (7.8)  0.8 [0.2–2.6] .69
 60%–80% 29 (8.7) 13 (20.3)  3.2 [1.0–10.0] .043
 <60% 9 (2.7) 23 (35.9)  5.9 [1.5–23.7] .012
Longest treatment interruption, log mean (SD), h 1.63 (0.28) 2.06 (0.48) <.0001 4.6 [1.3–16.9] .02
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multivariate analysis, adjusting for age, sex, CD4 cell count, 
group (starting, switching, and failing), and baseline HIV-
RNA. No emerging mutation conferring resistance to INSTI 
was detected in the dolutegravir group with detectable HIV-
RNA, in contrast with the raltegravir group. Taken together, 
these results suggest that dolutegravir-based ARV therapies 
are more forgiving to missed doses (either by average adher-
ence or treatment interruptions) than the other investigated 
ARVs regarding the risk of HIV-RNA replication. In addi-
tion, dolutegravir-based triple therapy is more forgiving to 
missed doses than raltegravir-based triple therapy regarding 
risk resistance.
Most of the previous studies in this area of research have 
attempted to identify an adherence threshold required for vi-
rological suppression with the aim to challenge the >95% his-
torical threshold. For example, Byrd et al. [8] reported that 75% 
average adherence defined by pharmacy refill to INSTI-based 
ARV therapy was required to suppress 90% of the treated pa-
tients. In this large cohort, first- and second-generation INSTIs 
were pooled, although we found that the level of forgiveness 
between dolutegravir and raltegravir strongly differed (as sug-
gested in Figure 2A and B, respectively). Overall, the multi-
variate analysis of the risk of virological replication (n = 399) 
(Table 1) is consistent with the >80% level of average adher-
ence found in other studies [2,7,8] but reaffirms the importance 
of treatment interruption length (adjusted odds ratio [aOR], 
4.6; 95% CI, 1.3–16.9; P =  .02) as an independent risk factor 
[9,10,16].
Importantly, the use of dolutegravir was significantly and 
independently associated with a lower risk of virological repli-
cation compared with other ARVs in the subgroup with lower 
adherence. Although the 95% confidence intervals were large 
due to the smaller sample size in this subgroup, this superi-
ority is consistent with a network meta-analysis of 20 random-
ized trials in which a significantly higher proportion of naïve 
PWH starting dolutegravir achieved virological suppression 
at week 96 compared with protease inhibitors, efavirenz, and 
cobicistat-boosted elvitegravir [17]. The pharmacokinetic for-
giveness of dolutegravir-based regimens is supported by the 
14-hour terminal elimination half-life of dolutegravir and its 
duration of inhibitory effect (>2-fold higher than the IC90 for 72 
hours after the last dose) [18]. In contrast, raltegravir, boosted 
atazanavir, and boosted lopinavir have shorter terminal elim-
ination half-lives: 10–12 hours [19], 8.3 hours, and 2.4 hours 
[20], respectively. NNRTIs do have a long plasma half-life but 
a relatively low genetic barrier to HIV-1 resistance. While pro-
longed plasma exposure improves pharmacokinetic forgiveness 
[21], a period of functional monotherapy following NNRTI-
based treatment interruption may select for low-frequency 
resistant strains. Despite a high genetic barrier, dolutegravir 
Second-generation INSTI (DTG, n = 102)
First-generation INSTI (RAL, n = 90)
NNRTI (NVP, n = 70; EFV, n = 12; RPV, n = 18)





























in hours (Log10 scale)
Figure 1. Virological replication levels (log HIV-RNA) at 6 months by EDM adherence pattern according to antiretroviral regimen class (n = 399). Each circle symbol repre-
sents a PWH connected to the plane by a vertical needle. The length of the needle represents the HIV-RNA level of replication at 6 months in log cp/mL (z-axis). The horizontal 
plane coordinates correspond to the EDM-defined adherence pattern during the 6-month period, with average adherence on the x-axis and the longest treatment interruption 
in log10 hours on the y-axis. PWH with higher adherence are those in the bottom corner. Abbreviations: ATV/r, atazanavir/ritonavir; bPI, boosted protease inhibitor; DTG, 
dolutegravir; EDM, electronic drug monitoring; EFV, efavirenz; LPV/r, lopinavir/ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PWH, people 
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monotherapy does promote INSTI-resistant strains [22], but 
only after a long period of exposure. This scenario is unlikely 
to occur when combined with other nucleosides in a fixed-dose 
combination or when combined with nucleotides dosed once 
daily whose anabolites have long intracellular half-lives.
There are several important limitations to this study. 
Adherence was monitored by EDM, so we cannot prove that 
the ARVs were ingested. The duration of the study, 6 months, 
was short, and any virologic breakthrough before 6 months re-
mained unnoticed. We compared nonrandomized groups of 
PWH with different baseline characteristics. In particular, the 
distribution of PWH who started treatment as a switch, treat-
ment failure, or first therapy was different among treatment 
groups (Table 1). The use of multivariate analysis adjusting 
for important predictors of virological replication may have 
contributed to attenuating this risk of bias, although residual 
confounding may remain. The cohorts comparing different 
treatment groups were not contemporaneously studied. We 
investigated dolutegravir-based triple therapy. Therefore, our 
results regarding dolutegravir should not be generalized to 
dual therapies (with either rilpivirine or lamivudine) or to 
Table 3. Predictors of Virological Replication by Average Adherence 
Subgroups in Multivariate Analysisa






aOR [95% CI] P Value aOR [95% CI] P Value
 Dolutegravir-based Ref.  Ref.  
 Raltegravir-based 3.7 [0.9–16.1] .08 45.6 [4.5–462.1] .001
 bPI-based 0.6 [0.1–3.1] .50 28.3 [3.4–239.4] .002
 NNRTI-based 3.4 [0.3–36.2] .31 24.8 [2.7–228.4] .005
Abbreviations: aOR, adjusted odds ratio; bPI, boosted protease inhibitor; NNRTI, non-
nucleoside reverse transcriptase inhibitor. 
aAdjusting for age, sex, baseline CD4 cell count, baseline HIV-RNA, and treatment group 
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bictegravir-based triple therapy. Further reseach in this area is 
warranted.
This study has also strengths. Our large sample size of 399 
PWH representing 73 017 EDM events with various ARVs in-
cluding dolutegravir makes this cohort unique. The diversity of 
ARV and adherence pattern behaviors allowed us to identify 
significant interactions between average adherence and treat-
ment interruption. While prior work has demonstrated that 
short-term treatment interruptions can be reliably predicted by 
average adherence [23], our results suggest that (i) they are not 
interchangeable measures [24] and (ii) their influence differs by 
ARV [21]. In addition, the use of historical controls allowed us 
to contrast virological outcomes with dolutegravir with older 
regimens at similar adherence patterns (Figure 2A–D) or dif-
ferent adherence strata (Table 3).
Consistently high adherence should remain the goal of treat-
ment, despite the high rates of suppression across a wide range 
of adherence levels, and patterns suggest a high degree of short-
term forgiveness on dolutegravir-based regimens. Low levels of 
tenofovir by dried blood spots predicted future virological rep-
lication among PWH receiving INSTI-based regimens (aOR, 
1.9; 95% CI, 1.0–3.4; P = .036) [25]. Moreover, suboptimal ad-
herence [26] to ARVs and ARV treatment interruptions [27] 
were both associated with higher levels of inflammation among 
people with full suppression and were associated with clinically 
significant morbidity in treated PWH [28].
As the World Health Organization recommends, the tran-
sition from NNRTI- to dolutegravir-based HIV treatment re-
gimens in resource-limited settings should limit the risk or 
resistance following unstructured drug interruption due to 
toxicities, poor retention in care, and drugs being out of stock 
locally. Our results are in line with the current International 
Antiviral Society–USA Panel guideline [29] in which sec-
ond-generation INSTIs are the preferred ARV treatment for 
most PWH. However, our results do not support the European 
AIDS Clinical Society 2020 guideline [30]. Starting a raltegravir-
based regimen as preferred initial antiretroviral therapy may 
expose PWH with suboptimal adherence to the risks of incom-
plete viral replication and potential emergence of resistance to 
INSTIs.
CONCLUSIONS
Our findings suggest that PWH treated with dolutegravir-based 
combination therapy may be at lower risk of detectable viro-
logical replication than those treated with older regimens at 
similar low to moderate adherence levels. While many factors 
not evaluated in this work should influence the choice of ARV 
therapy, including tolerance, pill burden, PWH preference, the 
risk of drug–drug interaction, and costs, we recommend using 
dolutegravir-based regimens for PWH who struggle to achieve 
high levels of adherence or are at risk of treatment interruptions.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
Acknowledgments
The authors wish to thank all participants and the staff from all 
participating centers, in particular Pascale Goubin, Arnaud de la 
Blanchardière, Sylvie Dargère, Aurélie Baldolli, Jocelyn Michon, and Anne 
Martin. 
Financial support. This work was funded by ViiV Healthcare.
Disclaimer. All operational aspects of the study, including monitoring, 
data collection, and statistical analyses, were managed by Caen University 
Hospital. The funder had no role in the study design, data collection, data 
analysis, data interpretation, or manuscript writing. All authors had final 
responsibility for the decision to submit for publication.
Potential conflicts of interest. J.-J.P.  reports personal fees and 
nonfinancial support from Gilead Sciences, MSD, and ViiV Healthcare out-
side the submitted work. L.C. reports personal fees and nonfinancial support 
from AbbVie, Janssen Cilag, Gilead Sciences, MSD, and ViiV Healthcare 
outside the submitted work. L.H. reports personal fees from AbbVie, Gilead, 
Janssen, Merck, and ViiV Healthcare outside the submitted work. All other 
authors: no reported conflicts. All authors have submitted the ICMJE Form 
for Disclosure of Potential Conflicts of Interest. Conflicts that the editors con-
sider relevant to the content of the manuscript have been disclosed.
Author contributions. All authors had full access to all the data in 
the study and take responsibility for the integrity of the data and the accu-
racy of the data analysis. J.-J.P., L.C., M.C., D.R.B., and L.H. contributed to 
the study concept and design. All authors were involved in acquisition of 
data. J.-J.P., A.L.F., J.-J.D., E.M.L., and F.C. analyzed data. J.-J.P., M.C., and 
L.H. contributed to clinical oversight of the study. J.-J.P. provided statistical 
expertise. J.-J.P., A.L.F., L.C., M.-P.S., D.R.B., M.C., R.V., and L.H. partici-
pated in data interpretation and drafted the report. All authors provided 
input to the report and approved the final version.
Prior presentation.  This work has been previously presented in part 
at the 12th International Conference on HIV Treatment and Prevention 
Adherence, held in Miami, Florida, June 4–6, 2017 (Abstract 389).
References
1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy 
and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21–30.
2. Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretro-
viral therapy and virologic failure. Medicine 2016; 95:e3361. 
3. Gardner  EM, Burman  WJ, Steiner  JF, et  al. Antiretroviral medication adher-
ence and the development of class-specific antiretroviral resistance. AIDS 2009; 
23:1035–46.
4. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily an-
tiretroviral treatment regimens for HIV infection: a meta-analysis of randomized 
controlled trials. Clin Infect Dis 2014; 58:1297–307.
5. Hemmige  V, Flash  CA, Carter  J, et  al. Single tablet HIV regimens facilitate 
virologic suppression and retention in care among treatment naïve patients. AIDS 
Care 2018; 30:1017–24.
6. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-
daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009; 48:484–8.
7. Viswanathan S, Detels R, Mehta SH, et al. Level of adherence and HIV RNA sup-
pression in the current era of highly active antiretroviral therapy (HAART). AIDS 
Behav 2015; 19:601–11.
8. Byrd  KK, Hou  JG, Hazen  R, et  al; Patient-Centered HIV Care Model Team. 
Antiretroviral adherence level necessary for HIV viral suppression using real-
world data. J Acquir Immune Defic Syndr 2019; 82:245–51.
9. Genberg  BL, Wilson  IB, Bangsberg  DR, et  al; MACH14 Investigators. Patterns 
of antiretroviral therapy adherence and impact on HIV RNA among patients in 
North America. AIDS 2012; 26:1415–23.
10. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resist-
ance in HIV-infected patients treated with nevirapine- or efavirenz-based antire-






/ofid/article/8/7/ofab316/6312665 by guest on 11 O
ctober 2021
8 • ofid • Parienti et al
11. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in Sub-
Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679–90.
12. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: 
sustained NNRTI treatment interruptions predict HIV rebound at low-to-
moderate adherence levels. PLoS One 2008; 3:e2783.
13. Parienti JJ, Ragland K, Lucht F, et al; ESPOIR and REACH study groups. Average 
adherence to boosted protease inhibitor therapy, rather than the pattern of missed 
doses, as a predictor of HIV RNA replication. Clin Infect Dis 2010; 50:1192–7.
14. Parienti  JJ, Barrail-Tran  A, Duval  X, et  al. Adherence profiles and therapeutic 
responses of treatment-naive HIV-infected patients starting boosted atazanavir-
based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother 
2013; 57:2265–71.
15. Gras G, Schneider MP, Cavassini M, et al. Patterns of adherence to raltegravir-
based regimens and the risk of virological failure among HIV-infected patients: 
the RALTECAPS cohort study. J Acquir Immune Defic Syndr 2012; 61:265–9.
16. Meresse M, March L, Kouanfack C, et al; Stratall ANRS 12110/ESTHER Study Group. 
Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in 
the Stratall ANRS 12110/ESTHER trial in Cameroon. HIV Med 2014; 15:478–87.
17. Nickel K, Halfpenny NJA, Snedecor SJ, Punekar YS. Comparative efficacy, safety 
and durability of dolutegravir relative to common core agents in treatment-naïve 
patients infected with HIV-1: an update on a systematic review and network 
meta-analysis. BMC Infect Dis 2021; 21:222.
18. Elliot E, Amara A, Jackson A, et al. Dolutegravir and elvitegravir plasma concentra-
tions following cessation of drug intake. J Antimicrob Chemother 2016; 71:1031–6.
19. Iwamoto  M, Wenning  LA, Petry  AS, et  al. Safety, tolerability, and pharmaco-
kinetics of raltegravir after single and multiple doses in healthy subjects. Clin 
Pharmacol Ther 2008; 83:293–9.
20. Boffito M, Else L, Back D, et al. Pharmacokinetics of atazanavir/ritonavir once 
daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessa-
tion. Antivir Ther 2008; 13:901–7.
21. Morrison  A, Stauffer  ME, Kaufman  AS. Relationship between adherence rate 
threshold and drug ‘forgiveness’. Clin Pharmacokinet 2017; 56:1435–40.
22. Hocqueloux  L, Raffi  F, Prazuck  T, et  al; MONCAY study group. Dolutegravir 
monotherapy versus dolutegravir/abacavir/lamivudine for virologically sup-
pressed people living with chronic human immunodeficiency virus infection: 
the randomized noninferiority monotherapy of tivicay trial. Clin Infect Dis 2019; 
69:1498–505.
23. Harris RA, Haberer JE, Musinguzi N, et al. Predicting short-term interruptions of 
antiretroviral therapy from summary adherence data: development and test of a 
probability model. PLoS One 2018; 13:e0194713.
24. Parienti JJ, Paterson DL. Number of missed doses: why 1 × 7 does not make 7 × 
1? AIDS 2012; 26:1437–40.
25. Morrow M, MaWhinney S, Coyle RP, et al. Predictive value of tenofovir diphos-
phate in dried blood spots for future viremia in persons living with HIV. J Infect 
Dis 2019; 220:635–42.
26. Castillo-Mancilla JR, Brown TT, Erlandson KM, et al. Suboptimal adherence to 
combination antiretroviral therapy is associated with higher levels of inflamma-
tion despite HIV suppression. Clin Infect Dis 2016; 63:1661–7.
27. Musinguzi  N, Castillo-Mancilla  J, Morrow  M, et  al. Antiretroviral therapy 
adherence interruptions are associated with systemic inflammation among 
ugandans who achieved viral suppression. J Acquir Immune Defic Syndr 2019; 
82:386–91.
28. Lederman MM, Funderburg NT, Sekaly RP, et al. Residual immune dysregulation 
syndrome in treated HIV infection. Adv Immunol 2013; 119:51–83.
29. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and pre-
vention of HIV infection in adults: 2020 recommendations of the International 
Antiviral Society-USA Panel. JAMA 2020; 324:1651–69.
30. European AIDS Clinical Society. Initial regimens: ART-naïve adult. Available at: 







/ofid/article/8/7/ofab316/6312665 by guest on 11 O
ctober 2021
